Denalitx and Biogen have registered the Phase 2b, randomized, double-blind, placebo-controlled (LUMA) study to determine the efficacy & safety of BIIB122 (LRRK2 inhibitor; DNL151) in 640 participants with #Parkinsons
Phase 2b study to determine the efficacy ... - Cure Parkinson's
Phase 2b study to determine the efficacy & safety of BIIB122 (LRRK2 inhibitor; DNL151) in 640 participants with Parkinsons
2 Replies
•
Key Inclusion criteria:.
.
.
. Screening genetic test results verifying the absence of a pathogenic leucine-rich repeat kinase 2 (LRRK2) variant.
it would be helpful if the clinical trials were done in more locations
Not what you're looking for?
You may also like...
Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials
Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
New clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
New clinical trial registered:
NeuromedIRCCS researchers have registered a small (N=20) open...
AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
AnnovisBio has initiated a 6-month, placebo-controlled, double-blind Phase 2 study to evaluate...
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
Highlights
• Oral NR increases brain NAD levels in individuals with Parkinson’s disease
• NR...
Related Posts
Results of a Phase 1b trial of MODAG's oligomer modulator anle138b evaluating the safety tolerability in healthy volunteers
Study finds overabundance of opportunistic pathogens in the guts of persons with Parkinson's
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease- Annovis Bio have published the results of their dose-finding, biomarker study of buntanetap in 14 early Alzheimers & 14 Parkinsons patients
Possible improvement of speech in Parkinsons patients with the encouragement and implementation of a daily walking routine.
